US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyntra Bio Inc

7.95

+0.17002.19%

Post-market: 7.950.00000.00%19:30 EDT

Volume:27.58K

Turnover:219.56K

Market Cap:32.16M

PE:0.18

High:8.05

Open:7.83

Low:7.80

Close:7.78

52wk High:12.60

52wk Low:6.32

Shares:4.05M

Float Shares:3.56M

Volume Ratio:1.31

T/O Rate:0.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):45.27

EPS(LYR):45.37

ROE:--

ROA:-22.50%

PB:-1.07

PE(LYR):0.18

Loading ...

Overview Company News Filings

Kyntra Bio Inc : Oppenheimer Initiates Coverage with Outperform Rating; Target Price $35

THOMSON REUTERS

Kyntra Bio shareholders approved executive pay in advisory vote at annual meeting

BRIEF-Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes

Kyntra Bio to present additional MATTERHORN trial data at EHA

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients With Anemia Due to Lower-Risk Myelodysplastic Syndromes

THOMSON REUTERS

Kyntra Bio - Roxadustat Shows No New Safety Signals in Lr-Mds Patients

THOMSON REUTERS

Kyntra Bio says Phase 3 MATTERHORN post-hoc analysis shows roxadustat lifts transfusion independence in lower-risk MDS

Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca

MT Newswires Live

Kyntra Bio Initiated at Buy by Rodman & Renshaw

Kyntra Bio initiated with a Buy at Rodman & Renshaw

Fluidra appoints Juan Graham CFO, succeeding Xavier Tintoré

Kyntra Bio CEO Thane Wettig buys 2,800 shares worth $19,852

Kyntra Bio Warned of Nasdaq Non‑Compliance, Faces Delisting Risk Without Remediation Plan by May 18, 2026

Kyntra Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Kyntra Bio Q1 net loss narrows to $15.1 million; revenue rises to $3.7 million

Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY

Benzinga Earnings

BRIEF-Kyntra Bio Inc Q1 Net Income USD -15.198 Million

Kyntra Bio Inc Q1 Revenue From Cont Ops USD 3.7 Million

THOMSON REUTERS

Press Release: Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Kyntra Bio Inc expected to post a loss of $3.35 a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/KYNB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYNB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","market":"US","secType":"STK","nameCN":"Kyntra Bio Inc","latestPrice":7.95,"timestamp":1788292800000,"preClose":7.78,"halted":0,"volume":27581,"hourTrading":{"tag":"盘后","latestPrice":7.95,"preClose":7.95,"latestTime":"19:30 EDT","volume":78,"amount":618,"timestamp":1788305405650,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02185089974293058,"floatShares":3561200,"shares":4045445,"eps":45.266125,"marketStatus":"Closed","change":0.17,"latestTime":"09-01 16:00:00 EDT","open":7.83,"high":8.0502,"low":7.8,"amount":219558.22780229998,"amplitude":0.032159,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":45.266125,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788336000000},"marketStatusCode":5,"adr":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":7.78,"preHourTrading":{"tag":"盘前","latestPrice":7.85,"preClose":7.78,"latestTime":"08:29 EDT","volume":337,"amount":2656.9098535,"timestamp":1788265799118,"change":0.07,"changeRate":0.008997,"amplitude":0.192802},"postHourTrading":{"tag":"盘后","latestPrice":7.95,"preClose":7.95,"latestTime":"19:30 EDT","volume":78,"amount":618,"timestamp":1788305405650,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.313656},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","floatShares":3561200,"roa":"-22.50%","roe":"--","lyrEps":45.371456,"volumeRatio":1.313656,"shares":4045445,"dividePrice":0,"high":8.0502,"amplitude":0.032159,"preClose":7.78,"low":7.8,"week52Low":6.32,"pbRate":"-1.07","psRate":"6.97","week52High":12.6,"institutionHeld":0,"latestPrice":7.95,"eps":45.266125,"divideRate":0,"volume":27581,"delay":0,"ttmEps":45.266125,"open":7.83,"prevYearClose":8.78,"prevWeekClose":8.02,"prevMonthClose":7.78,"prevQuarterClose":7.55,"fiveDayClose":8.1,"twentyDayClose":6.92,"sixtyDayClose":6.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYNB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"KYNB","fiscalQuarterEnding":"2026/06","expectedEps":-3.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-4.68},{"market":"US","date":"2026-05-11","symbol":"KYNB","fiscalQuarterEnding":"2026/03","expectedEps":-3.36,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-3.74},{"market":"US","date":"2026-03-16","symbol":"KYNB","fiscalQuarterEnding":"2025/12","expectedEps":-3.89,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"post","actualEps":-3.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYNB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYNB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1783396800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYNB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYNB","date":"2026-08-31","current":0.175628,"percent":0.85,"low":0.128311,"twenty":0.150051,"median":0.163953,"eighty":0.174182,"high":0.188779,"avg":0.161946,"sd":0.014741,"marketCap":32473974},"quantilePoints":[{"date":"2026-01-09","current":0.17821,"twenty":0.178998,"median":0.18018,"eighty":0.181362,"marketCap":38431727},{"date":"2026-01-16","current":0.170144,"twenty":0.170369,"median":0.172958,"eighty":0.17821,"marketCap":36692186},{"date":"2026-01-23","current":0.168268,"twenty":0.168268,"median":0.171269,"eighty":0.17821,"marketCap":36287641},{"date":"2026-01-30","current":0.150259,"twenty":0.160389,"median":0.169206,"eighty":0.172958,"marketCap":32404014},{"date":"2026-02-06","current":0.140692,"twenty":0.153073,"median":0.163953,"eighty":0.171457,"marketCap":30340837},{"date":"2026-02-13","current":0.140317,"twenty":0.147445,"median":0.160201,"eighty":0.171269,"marketCap":30259928},{"date":"2026-02-20","current":0.14707,"twenty":0.146282,"median":0.158795,"eighty":0.170369,"marketCap":31716288},{"date":"2026-02-27","current":0.13075,"twenty":0.144894,"median":0.154199,"eighty":0.170144,"marketCap":28196751},{"date":"2026-03-06","current":0.129155,"twenty":0.137315,"median":0.150635,"eighty":0.168643,"marketCap":27852888},{"date":"2026-03-13","current":0.131688,"twenty":0.133714,"median":0.147445,"eighty":0.165191,"marketCap":28399023},{"date":"2026-03-20","current":0.161033,"twenty":0.133301,"median":0.147633,"eighty":0.164047,"marketCap":29541837},{"date":"2026-03-27","current":0.144268,"twenty":0.133714,"median":0.1489,"eighty":0.163953,"marketCap":26466248},{"date":"2026-04-02","current":0.156621,"twenty":0.135327,"median":0.1489,"eighty":0.163094,"marketCap":28732471},{"date":"2026-04-10","current":0.158607,"twenty":0.13649,"median":0.150021,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-17","current":0.158607,"twenty":0.137128,"median":0.152651,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-24","current":0.154658,"twenty":0.137616,"median":0.154087,"eighty":0.16165,"marketCap":28372304},{"date":"2026-05-01","current":0.160371,"twenty":0.138929,"median":0.154658,"eighty":0.161209,"marketCap":29420432},{"date":"2026-05-08","current":0.156671,"twenty":0.140092,"median":0.155492,"eighty":0.161033,"marketCap":28741595},{"date":"2026-05-15","current":0.173439,"twenty":0.140542,"median":0.155518,"eighty":0.16165,"marketCap":28377265},{"date":"2026-05-22","current":0.171707,"twenty":0.141779,"median":0.155761,"eighty":0.163953,"marketCap":28093897},{"date":"2026-05-29","current":0.173687,"twenty":0.143209,"median":0.156128,"eighty":0.168258,"marketCap":28417746},{"date":"2026-06-05","current":0.168491,"twenty":0.144709,"median":0.156621,"eighty":0.168887,"marketCap":27567642},{"date":"2026-06-12","current":0.167254,"twenty":0.145601,"median":0.156867,"eighty":0.168639,"marketCap":27365237},{"date":"2026-06-18","current":0.170965,"twenty":0.145982,"median":0.157197,"eighty":0.169431,"marketCap":27972453},{"date":"2026-06-26","current":0.171707,"twenty":0.14617,"median":0.158138,"eighty":0.170144,"marketCap":28093897},{"date":"2026-07-02","current":0.1868,"twenty":0.14632,"median":0.158607,"eighty":0.170718,"marketCap":30563245},{"date":"2026-07-10","current":0.181109,"twenty":0.146883,"median":0.158743,"eighty":0.171457,"marketCap":29632179},{"date":"2026-07-17","current":0.182841,"twenty":0.14707,"median":0.160014,"eighty":0.171955,"marketCap":29915547},{"date":"2026-07-24","current":0.174924,"twenty":0.147445,"median":0.160711,"eighty":0.173192,"marketCap":28620151},{"date":"2026-07-31","current":0.167996,"twenty":0.147746,"median":0.161253,"eighty":0.173241,"marketCap":27486680},{"date":"2026-08-07","current":0.172709,"twenty":0.148684,"median":0.162522,"eighty":0.173005,"marketCap":28257845},{"date":"2026-08-14","current":0.174182,"twenty":0.14943,"median":0.163953,"eighty":0.173489,"marketCap":28498708},{"date":"2026-08-21","current":0.161795,"twenty":0.149739,"median":0.162522,"eighty":0.173439,"marketCap":29639587},{"date":"2026-08-28","current":0.176825,"twenty":0.149997,"median":0.163953,"eighty":0.174182,"marketCap":32392992},{"date":"2026-08-31","current":0.177267,"twenty":0.150051,"median":0.163953,"eighty":0.174182,"marketCap":32473974}],"updateTime":1788316170871},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYNB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649198791","title":"Kyntra Bio Inc : Oppenheimer Initiates Coverage with Outperform Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2649198791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649198791?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:18","pubTimestamp":1783426716,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643755873","title":"Kyntra Bio shareholders approved executive pay in advisory vote at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643755873","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643755873?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:02","pubTimestamp":1781604143,"startTime":"0","endTime":"0","summary":"Kyntra Bio held its annual shareholder meeting on June 12, 2026.Shareholders elected Michael Kauffman, M.D., Ph.D., as a Class III director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL2vhk07:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642346662","title":"BRIEF-Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642346662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642346662?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:35","pubTimestamp":1781210145,"startTime":"0","endTime":"0","summary":"BRIEF-Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic SyndromesJune 11 (Reuters) - Kyntra Bio Inc KYNB.O:KYNTRA BIO PRESENTS NEW ROXAD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642159234","title":"Kyntra Bio to present additional MATTERHORN trial data at EHA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642159234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642159234?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:20","pubTimestamp":1781209200,"startTime":"0","endTime":"0","summary":"Kyntra Bio (KYNB) announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with ane...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyntra-bio-to-present-additional-matterhorn-trial-data-at-eha-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyntra-bio-to-present-additional-matterhorn-trial-data-at-eha-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642319002","title":"Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients With Anemia Due to Lower-Risk Myelodysplastic Syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642319002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642319002?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:05","pubTimestamp":1781208349,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642231137","title":"Kyntra Bio - Roxadustat Shows No New Safety Signals in Lr-Mds Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642231137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642231137?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:05","pubTimestamp":1781208349,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0YU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642151231","title":"Kyntra Bio says Phase 3 MATTERHORN post-hoc analysis shows roxadustat lifts transfusion independence in lower-risk MDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2642151231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642151231?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:05","pubTimestamp":1781208347,"startTime":"0","endTime":"0","summary":"Kyntra Bio flagged new post hoc Phase 3 MATTERHORN data on roxadustat in lower-risk MDS anemia, set for presentation at EHA 2026.The analysis showed higher transfusion independence with roxadustat versus placebo, supporting a potential differentiated option in a hard-to-treat setting.Benefits appeared consistent across ring sideroblast-positive and ring sideroblast-negative disease, widening the potential addressable patient pool.A pivotal Phase 3 trial in high transfusion burden patients is being finalized with FDA input, with initiation targeted for 2H 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLtvM8m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","NDAQ","SG9999014013.SGD","BK4588","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014021.USD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286344","title":"Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286344?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:00","pubTimestamp":1781089211,"startTime":"0","endTime":"0","summary":"Kyntra Bio  has received $4 million from AstraZeneca Treasury , completing the payments for their 2025 share purchase agreement, Kyntra Bio said in a Tuesday filing.In 2025, Kyntra Bio sold its Chinese operations to AstraZeneca for about approximately $220 million and the $4 million payment is second and final holdback under the deal, according to the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443382.USD","KYNB","BK4007","BK4585","LU0889565916.HKD","LU2417539215.USD","LU2237443978.SGD","LU2237443622.USD","LU0058720904.USD","LU1829250122.USD","LU2237443895.HKD","LU0320765992.SGD","LU0289739699.SGD","LU2456880835.USD","AZNH","IE00B3T34201.USD","LU2237443465.HKD","LU2462157665.USD","LU0109394709.USD","BK4588","BK4568","LU2236285917.USD","AZN","LU2237443549.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642584467","title":"Kyntra Bio Initiated at Buy by Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2642584467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642584467?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:01","pubTimestamp":1781006460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYNB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 08:01 ET (12:01 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642846289","title":"Kyntra Bio initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2642846289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642846289?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:16","pubTimestamp":1781003807,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $30 price target The company has a first-in-class CD46-targeting ant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyntra-bio-initiated-with-a-buy-at-rodman-renshaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyntra-bio-initiated-with-a-buy-at-rodman-renshaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638389650","title":"Fluidra appoints Juan Graham CFO, succeeding Xavier Tintoré","url":"https://stock-news.laohu8.com/highlight/detail?id=2638389650","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638389650?lang=en_us&edition=fundamental","pubTime":"2026-05-28 14:37","pubTimestamp":1779950268,"startTime":"0","endTime":"0","summary":"Fluidra appointed Juan Graham as chief financial officer, effective June 1, 2026.Outgoing CFO Xavier Tintoré will step down on Aug. 1, 2026, remaining through year-end to support the transition.Graham brings 25+ years in senior finance roles, including nearly two decades at Johnson & Johnson.He most recently served as CFO at U.S.-listed FibroGen, later at Perspective Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fluidra SA published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL4BpCCw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1043141123.HKD","IE0002270589.USD","BK4532","IE00BLSP4239.USD","LU2129689431.USD","LU0114720955.EUR","LU1023059063.AUD","BK4534","LU1228905540.USD","LU2456880835.USD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","LU0426417589.USD","LU2471134879.HKD","IE000MB6IJN5.SGD","LU0053666078.USD","LU0124676726.USD","LU0345770308.USD","BK4550","LU0795875086.SGD","IE00BFXG1179.USD","LU1066053197.SGD","IE0034235303.USD","LU0964807845.USD","JNJ","LU1983299246.USD","LU1066051225.USD","LU1732799900.SGD","LU0098860793.USD","LU1506573853.SGD","IE00BN8TJ469.HKD","IE00B42XCP33.USD","LU1778281490.HKD","LU0943347566.SGD","IE000SO60NU8.SGD","LU0820562030.AUD","LU1496350502.SGD","LU2403377893.USD","LU2430703178.SGD","IE00BDGV0183.EUR","IE00BGHQF631.EUR","IE00BZ1G4Q59.USD","BK4504","LU0792757196.USD","KYNB","LU2505996681.GBP","IE0001KFT4U8.USD","BK4568","LU1551013342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078719","title":"Kyntra Bio CEO Thane Wettig buys 2,800 shares worth $19,852","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078719","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078719?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105650,"startTime":"0","endTime":"0","summary":"Thane Wettig, CEO and director, reported the purchase of 2,800 Kyntra Bio common shares at USD 7.09.The filing also listed 40 shares held indirectly by a spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL2KTX85:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Kyntra Bio CEO Thane Wettig buys 2,800 shares worth $19,852","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635760802","title":"Kyntra Bio Warned of Nasdaq Non‑Compliance, Faces Delisting Risk Without Remediation Plan by May 18, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635760802","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635760802?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:01","pubTimestamp":1778738475,"startTime":"0","endTime":"0","summary":"Kyntra Bio, Inc. (KYNB) has disclosed a new risk, in the Share Price & Shareholder Rights category. Kyntra Bio, Inc. faces a significant listing ri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kyntra-bio-warned-of-nasdaq-non‑compliance-faces-delisting-risk-without-remediation-plan-by-may-18-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kyntra-bio-warned-of-nasdaq-non‑compliance-faces-delisting-risk-without-remediation-plan-by-may-18-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYNB","BK4139","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258122","title":"Kyntra Bio Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258122","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258122?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:02","pubTimestamp":1778533368,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc reports results for the quarter ended March 31 - Earnings SummaryKyntra Bio Inc KYNB.OQ reported a quarterly adjusted loss of $3.76 per share for the quarter ended March 31, lower than ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634823207","title":"Kyntra Bio Q1 net loss narrows to $15.1 million; revenue rises to $3.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634823207","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634823207?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:09","pubTimestamp":1778530172,"startTime":"0","endTime":"0","summary":"Kyntra Bio posted Q1 2026 revenue of USD 3.74 million, up 36.5% year over year, while net loss from continuing operations narrowed to USD 15.1 million.Loss per share from continuing operations improved to USD 3.74, from USD 4.15 a year earlier.Cash, cash equivalents, investments, and accounts receivable totaled USD 100.3 million at March 31, supporting cash runway into 2028.Phase 2 FG-3246 monotherapy trial in metastatic castration-resistant prostate cancer remained on track for interim analysis in 4Q 2026.Protocol for pivotal Phase 3 roxadustat trial in lower-risk MDS anemia with high transfusion burden is being finalized following FDA feedback, with trial initiation targeted for second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL4y09YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","KYNB","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634732232","title":"Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2634732232","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634732232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:09","pubTimestamp":1778530146,"startTime":"0","endTime":"0","summary":"Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent decrease over earnings of $1.15 per share from the same period last year.  The company reported $3.738 million in sales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52468251/kyntra-bio-q1-eps-3-76-down-from-1-15-yoy-sales-3-738m-up-from-2-739m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634286232","title":"BRIEF-Kyntra Bio Inc Q1 Net Income USD -15.198 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634286232","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634286232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529948,"startTime":"0","endTime":"0","summary":"BRIEF-Kyntra Bio Inc Q1 Net Income USD -15.198 Million\n\n\nMay 11 (Reuters) - Kyntra Bio Inc Q1 net income from cont ops USD -15.1 million.\n\nQ1 revenue from cont ops USD 3.7 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nPLX4E0ECE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634329362","title":"Kyntra Bio Inc Q1 Revenue From Cont Ops USD 3.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634329362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634329362?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nPLX4E0ECE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232793","title":"Press Release: Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232793","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232793?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529900,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer  is progressing well with the interim analysis. -- Positive results from the investigator-sponsored study of FG-3246 in. combination with enzalutamide in patients with mCRPC were presented at. ASCO GU in February 2026, further validating key Phase 2 monotherapy. -- Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia. in patients with lower-risk myelodysplastic syndromes  and high. -- Kyntra Bio to host conference call and webcast presentation today at 5:00. Key Highlights of First Quarter, Recent Developments, and Upcoming Milestones. targeting CD46, in mCRPC is actively enrolling and remains on track for. -- Higher tumor uptake of FG-3180 was numerically associated with","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TM","BK4109","BK4231","BK4585","LU0211328371.USD","03160","BK4232","DD","BK4555","BK4604","KYNB","BK4022","R","LU1267930227.SGD","LU2236285917.USD","LU0310799852.SGD","BK4504","LU0310800965.SGD","BK4588","ADC","BK4099","LU1267930490.SGD","LU0211327993.USD","LU0128525689.USD","LU0052756011.USD","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634717462","title":"Kyntra Bio Inc  expected to post a loss of $3.35 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634717462","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634717462?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:49","pubTimestamp":1778273345,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc  expected to post a loss of $3.35 a share - Earnings Preview Kyntra Bio Inc KYNB.OQ KYNB.O is expected to  show a fall in quarterly revenue when it reports  results on May 11 for the pe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":50,"code":"91000000","status":"200"}]}}